

Homerton University Hospital NHS Foundation Trust  
 Hackney College  
 Defoe Building, Room 10  
 50 Hoxton Street  
 N1 6LP

Date 08<sup>th</sup> June 2016

**Email:** [foi@homerton.nhs.uk](mailto:foi@homerton.nhs.uk)

Dear Sir or Madam,

**Ref: FOI 2486**

Thank you for your recent Freedom of Information request regarding the treatment of patients Hepatocellular Carcinoma at Homerton Hospital.

The Trust can provide the following information:

**Within your trust how many unique patients with Hepatocellular Carcinoma (C220) have been treated in the past 12 months?  
 How many patients with with Hepatocellular Carcinoma have received?**

Bevacizumab (Avastin)	
Everolimus (Afinitor)	
Lapatinib (Tyverb)	
Sorafenib (Nexavar)	
Sunitinib (Sutent)	

**Within your trust how many unique patients with Gastrointestinal Stromal Tumours (C269) have been treated in the past 12 months?  
 How many patients with with Gastrointestinal Stromal Tumours have received?**

Dasatinib (Sprycel)	
Imatinib (Glivec)	
Nilotinib (Tasigna)	
Pazopanib (Votrient)	
Regorafenib (Stivarga)	
Sorafenib (Nexavar)	
Sunitinib (Sutent)	

We do not treat Hepatocellular Carcinoma (C220) and Gastrointestinal Stromal Tumours (C269) here at the Homerton hospital, they are all referred to Royal London Hospital /NHS Barts for treatment.

If you have any queries about this response please contact the information governance manager at [foi@homerton.nhs.uk](mailto:foi@homerton.nhs.uk) , in the first instance. If following that, you still have any concerns, you may contact the Information Commissioner either by letter, FOI/EIR Complaints resolution, Wycliffe House, Water Lane, Wilmslow, Cheshire SM9 5AF, or by email [www.informationcommissioner.gov.uk](http://www.informationcommissioner.gov.uk) to take them further.

### Copyright Statement

The material provided is subject to the HUHFT's copyright unless otherwise indicated. Unless expressly indicated on the material to the contrary, it may be reproduced free of charge in any format or medium, provided it is reproduced accurately and not used in a misleading manner. Where any of the copyright items are being re-published or copied to others, you must identify the source of the material and acknowledge the copyright status. Permission to reproduce material does not extend to any material accessed through the Publication Scheme that is the copyright of third parties. You must obtain authorisation to reproduce such material from the copyright holders concerned.

Yours sincerely

Mohamed Uddin  
FoI Administrator

Mike Dunne  
Information Governance Manager